Parallel lead optimization

Industrialization of Drug Discovery: From Target Selection Through Lead Optimization

Volumn , Issue , 2005, Pages 137-163

  Gallion, Steven L ^a   Beresford, Alan ^b   Bey, Philippe ^a  

^a Cellular Genomics Inc ^*  (United States)

^b Inpharmatica Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889875474     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (162)

1. T Kennedy. Managing the drug discovery/development interface. Drug Discov Today 2:436, 1997.
2. Outlook 2002. Boston: Tufts Center for the Study of Drug Development, 2002.
3. F Douglas. Integrated Strategies to Increase R&D Productivity. Paper presented at Drug Discovery and Technology Leaders Summit, Montreux, Switzerland, June 2003.
4. EL Allan. Balancing quantity and quality in drug discovery. Drug Discov World 4:71-75, 2002/2003.
5. JA DiMasi. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther 69:297-307, 2001.
6. RA Lipper. E pluribus product: how can we optimize selection of drug development candidates from many compounds at an early stage? Mod Drug Discov 2:55-60, 1999.
7. RA Goodnow, Jr. Current practices in generation of small molecule new leads. J Cell Biochem Suppl 37:13-21, 2001.
8. AD Baxter, PM Lockey. "Hit" to "lead" and "lead" to "candidate" optimization using multi-parametric principles. Drug Discov World 2:9-15, 2001.
9. GW Caldwell. Compound optimization in early and late phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Curr Opin Drug Discov Dev 3:30-41, 2000.
10. RA Edwards, K Zhang, L Firth. Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development. Drug Discov World 3:67-71, 2002.
11. JA DiMasi. Uncertainty in drug development: approval success rates for new drugs. In Clinical Trials and Tribulations, 2nd ed., revised and expanded, AE Cato, L Sutton, A Catto III, Eds. New York: Marcel Dekker, 2002, chap. 20, pp. 361-377.
12. DB Lakins. Nonclinical drug development: pharmacology, drug metabolism, and toxicology. New Drug Approv 100:17-54, 2000.
13. N Bodor, P Buchwald. Soft drug design: general principles and recent applications. Med Res Rev 20:58-101, 2000.
14. H van de Waterbeemd, DA Smith, BC Jones. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 15:273-286, 2001.
15. AP Beresford, HE Selick, MH Tarbit. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today 7:109-116, 2002.
16. I Kariv, RA Rourick, DB Kassel, TDY Chung. Improvement of "hit-to-lead" optimization by integration of in vitro HTS Experimental models for early determination of pharmacokinetic properties. Comb Chem High Throughput Screen 5:459-472, 2002.
17. SJF MacDonald, PW Smith. Lead optimization in 12 months? True confessions of a chemistry team. Drug Discov Today 6:947-953, 2001.
18. GW Caldwell, DM Ritchie, JA Masucci, W Hageman, Z Yan. The new preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top Med Chem 1:353-366, 2001.
19. PJ Eddershaw, AP Beresford, MK Bayliss. ADME/PK as part of a rational approach to drug discovery. Drug Discov Today 5:409-414, 2000.
20. AR Leach, MM Hann. The in silico world of virtual libraries. Drug Discov Today 5:326-336, 2000.
21. H Matter, KH Baringhaus, T Naumann, T Klabunde, B Pirard. Computational approaches toward the rational design of drug-like compound libraries. Comb Chem High Throughput Screen 4:453-457, 2001.
22. WJ Egan, WP Walters, MA Murcko. Guiding molecules toward drug-likeness. Curr Opin Drug Discov Dev 5:540-549, 2002.
23. LB Kinter, JP Valentin. Safety pharmacology and risk assessment. Fundam Clin Pharmacol 16:175-182, 2002.
24. DJ Snodin. An EU perspective on the use of in vitro methods in regulatory toxicology. Toxicol Lett 127:161-168, 2002.
25. BH Migdalof. Methods for obtaining drug time course data from individual small laboratory animals: serial microblood sampling and assay. Drug Metab Rev 5:295-310, 1976.
26. WM Williams. A chronically implantable arterial catheter for use in unrestrained small animals. J Neurosci Methods 12:195-203, 1985.
27. RE White, P Manitpisitkul. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab Dispos 29:957-966, 2001.
28. WA Korfmacher, KA Cox, KJ Ng, J Veals, Y Hsieh, S Wainhaus, L Broske, D Prelusky, A Nomeir, RE White. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun Mass Spectrosc 15:335-240, 2001.
29. PM Timmerman, R de Vries, BA Ingelse. Tailoring bioanalysis for PK studies supporting drug discovery. Curr Top Med Chem 1:443-462, 2001.
30. BL Ackermann, MJ Berna, AT Murphy. Recent advances in use of LC/MS/ MS for quantitative high-throughput bioanalytical support of drug discovery. Curr Top Med Chem 2:53-66, 2002.
31. T Ohkawa, Y Ishida, E Kanaoka, K Takahashi, H Okabe, T Matsumoto, S Nakamoto, J Tamada, M Koike, T Yoshikawa. A new generic column switching system for quantitation in cassette dosing using LC/MS/MS. J Pharm Biomed Anal 31:1089-1099, 2003.
32. SS Pochapsky, TC Pochapsky. Nuclear magnetic resonance as a tool in drug discovery, metabolism and disposition. Curr Top Med Chem 1:427-441, 2001.
33. AP Watt, RJ Mortishire-Smith, U Gerhard, SR Thomas. Metabolite identification in drug discovery. Curr Opin Drug Discov Dev 6:57-65, 2003.
34. LL Rolf Jr, KE Bartels, EC Nelson, KD Berlin. Chronic Bile duct cannulation in laboratory rats. Lab Anim Sci 41:486-492, 1991.
35. M Bickel, HF Brettel, S Jung, R Schleyerbach. A New model for demonstrating the hepatic first-pass effect. Arzneimittelforschung 27:1879-1881, 1977.
36. K Tabata, K Yamaoka, T Fukuyama, T Nakagawa. Evaluation of Intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of Diclofenac. Pharm Res 12:880-883, 1995.
37. JH Strubbe, JE Bruggink, AB Steffens. Hepatic portal vein cannulation for infusion and blood sampling in freely moving rats. Physiol Behav 65:885-887, 1999.
38. RG Sample, GV Rossi, EW Packman. Thiry-Vella dog as a biologic model for evaluation of drug absorption from the intestinal mucosa. J Pharm Sci 57:795-798, 1968.
39. N Hashimoto, H Ohyanagi. Systemic factors are trophic in Thiry-Vella loop in the absence of luminal contents. Hepatogastroenterology 49:428-431, 2002.
40. RD Evans, MJ Bennett, D Hauton. Perfused heart studies to investigate lipid metabolism. Biochem Soc Trans 28:113-120, 2000.
41. HM Mehendale, LS Angevine, Y Ohmiya. The isolated perfused lung: a critical evaluation. Toxicology 21:1-36, 1981.
42. RW Niemeier. The isolated perfused lung. Environ Health Perspect 56:35-41, 1984.
43. A Zarzuelo, A Sanchez-Navarro, FG Lopez, JM Lanao. A review of the isolated kidney as an experimental model for pharmacokinetic studies. Methods Find Exp Clin Pharmacol 22:757-763, 2000.
44. KL Brouwer, RG Thurman. Isolated perfused liver. Pharm Biotechnol 8:161-192, 1996.
45. JW Porteous. Intestinal metabolism. Environ Health Perspect 33:25-35, 1979.
46. H Bohets, P Annaert, G Mannens, L van Beijsterveldt, K Anciaux, P Verboven, W Meuldermans, K Lavrijsen. Strategies for Absorption screening in drug discovery and development. Curr Top Med Chem 1:367-383, 2001.
47. HF Woods, MB Youdim. The isolated perfused rat brain preparation: a critical assessment. Essays Neurochem Neuropharmacol 2:49-69, 1977.
48. Z Hu, PG Wells. Modulation of benzo[a]pyrene bioactivation by glucuronidation in lymphocytes and hepatic microsomes from rats with a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. Toxicol Appl Pharmacol 127:306-313, 1994.
49. Gonzalez FJ. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol Lett 120:199-208, 2001.
50. F Gonzalez, S Kimura. Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys 409:153-158, 2003.
51. JH Lin, M Yamazaki. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59-98, 2003.
52. SA Roberts. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 31:557-589, 2001.
53. G Severin. A novel column/buffer combination for chromatographic analysis of basic drugs in simulated gastrointestinal fluids. J Pharm Sci 75:211-214, 1986.
54. P Artursson, K Palm, K Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Delivery Syst 22:67-84, 1996.
55. JD Irvine, L Takahashi, K Lockhart, J Cheong, JW Tolan, HE Selick, JR Grove. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28-33, 1999.
56. WS Putnam, S Ramanathan, L Pan, LH Takahashi, LZ Benet. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci 91:2622-2635, 2002.
57. FR Luo, PV Paranjpe, A Guo, E Rubin, P Sinko. Intestinal transport of irinotecan in Caco-2 cells and MDCK cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos 30:763-770, 2002.
58. A Avdeef, M Strafford, E Block, MP Balogh, W Chambliss, I Khan. Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst. Eur J Pharm Sci 14:271-280, 2001.
59. IJ Hidalgo. Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 1:385-401, 2001.
60. I Megard, A Garrigues, S Orlowski, S Jorajuria, P Clayette, E Ezan, A Mabondzo. A co-culture-based model of human blood-brain barrier: application to active transport of Indinavir and in vivo-in vitro correlation. Brain Res 927:153-167, 2002.
61. I Kariv, H Cao, KR Oldenburg. Development of a high throughput equilibrium dialysis method. J Pharm Sci 90:580-587, 2001.
62. LN Sansom, AM Evans. What is the true clinical significance of plasma protein binding displacement interactions? Drug Safety 12:227-233, 1995.
63. SA Wrighton, M Vandenbranden, JC Stevens, LA Shipley, BJ Ring, AE Rettie, JR Cashman. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 25:453-484, 1993.
64. K Venkatakrishnan, LL Von Moltke, DJ Greenblatt. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharm 41:1149-1179, 2001.
65. MN Berry, AR Grivell, MB Grivell, JW Phillips. Isolated hepatocytes: past, present and future. Cell Biol Toxicol 13:223-233, 1997.
66. D Runge, C Kohler, VE Kostrubsky, D Jager, T Lehmann, DM Runge, U May, DB Stolz, SC Strom, WE Fleig, GK Michalopoulos. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273:333-341, 2000.
67. RJ Edwards, RJ Price, PS Watts, AB Renwick, JM Tredger, AR Boobis, BG Lake. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31:282-288, 2003.
68. PJ Eddershaw, M Dickins. Advances in drug metabolism screening. Pharm Sci Technol Today 3:13-19, 1999.
69. AP Beresford. CYP1A1: friend or foe? Drug Metab Rev 25, 503-517, 1993.
70. R Curi-Pedrosa, M Daujat, L Pichard, JC Ourlin, P Clair, L Gervot, P Lesca, J Domergue, H Joyeux, G Fourtanier. Omeprazole and Lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 269:384-392, 1994.
71. AP Beresford, WJ Ellis, J Ayrton, MA Johnson, DFV Lewis. Cytochrome P450 1A (CYP1A) induction in rat and man by the benzodioxino derivative, Fluparoxan. Xenobiotica 27:159-173, 1997.
72. J Pan, Q Xiang, AB Renwick, RJ Price, SE Ball, J Kao, JA Scatina, BG Lake. Use of real-time reverse transcription-polymerase chain reaction method to study the induction of CYP1A, CYP1A2 and CYP4A forms in precision-cut rat liver slices. Xenobiotica 32:739-747, 2002.
73. JL Staudinger, A Madan, KM Carol, A Parkinson. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab Dispos 31:523-527, 2003.
74. G Luo, M Cunningham, S Kim, T Burn, J Lin, M Sinz, G Hamilton, C Rizzo, S Jolley, D Gilbert, A Downey, D Mudra, R Graham, K Carroll, J Xie, A Madan, A Parkinson, D Christ, B Selling, E LeCluyse, LS Gan. CYP3A4 induction by drugs: correlation between a Pregnane-X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804, 2002.
75. PD Worboys, DJ Carlile. Implications and consequences of enzyme induction on preclinical and clinical development. Xenobiotica 31:539-556, 2001.
76. F De Clerck, A van de Water, J D'Aubioul, HR Lu, K van Rossem, A Hermans, K van Ammel. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol 16:125-140, 2002.
77. F De Ponti, E Poluzzi, A Cavalli, M Recanatini, N Montanaro. Safety of nonantiarrhythmic drugs that prolong the QT interval or induce Torsade de Pointes: an overview. Drug Safety 25:263-286, 2002.
78. B Surawicz. Torsades de Pointes: unanswered questions. J Nippon Med School 69:218-223, 2002.
79. DC Blanchard, G Griebel, RJ Blanchard. The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharm 463:97-116, 2003.
80. DA Groneberg, C Grosse-Siestrup, A Fischer. In vitro models to study hepatotoxicity. Toxicol Pathol 30:394-399, 2002.
81. BL Pool, D Schmahl. What is new in mutagenicity and carcinogenicity: status of short-term assay systems as tools in genetic toxicology and carcinogenesis. Pathol Res Pract 182:704-712, 1987.
82. D Purves, C Harvey, D Tweats, CE Lumley. Genotoxicity testing: current practices and strategies used by the pharmaceutical industry. Mutagenesis 10:297-312, 1995.
83. PJ Kramer. Genetic toxicology. J Pharm Pharmacol 50:395-405, 1998.
84. K Muller-Tegethoff, B Kersten, P Kasper, L Muller. Applications of the in vitro rat hepatocyte micronucleus assay in genetic toxicology testing. Mutat Res 392:125-138, 1997.
85. K Mortelmans, E Zeiger. The Ames Salmonella/microsome mutagenicity assay. Mutat Res 455:29-60, 2000.
86. JH Weisburger. Antimutagenesis and anticarcinogenesis, from the past to the future. Mutat Res 480/481:23-35, 2001.
87. P Moller, LE Knudsen, S Loft, H Wallin. The comet assay as a rapid test in biomonitoring occupational exposure to DNA-damaging agents and effect of confounding factors. Cancer Epidemiol Biomarkers Prevent 9:1005-1015, 2000.
88. S Pavanello, E Clonfero. Biomarkers of genotoxic risk and metabolic polymorphism. La Medicina Lavaro 91:431-469, 2000.
89. RJ Albertini. HPRT mutations in humans: biomarkers for mechanistic studies. Mutat Res 489:1-16, 2001.
90. AR Collins. The comet assay. Principles, applications, and limitations. Methods Mol Biol 203:163-177, 2002.
91. C Schleger, N Krebsfaenger, A Kalkuhl, R Bader, T Singer. Innovative cell culture methods in drug development. Alternativen Tierexperimenten 18:5-8, 2001.
92. PJ Bugelski, U Atif, S Molton, I Toeg, PG Lord, DG Morgan. A strategy for high throughput cytotoxicity screening in pharmaceutical toxicology. Pharm Res 17:1265-1272, 2000.
93. SM Evans, A Casartelli, E Herreros, DT Minnick, C Day, E George, C Westmoreland. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicol In Vitro 15:579-584, 2001.
94. S Kohler, S Belkin, RD Schmid. Reporter gene bioassays in environmental analysis. Fresenius' J Anal Chem 366:769-779, 2000.
95. VA Baker. Endocrine disrupters: testing strategies to assess human hazard. Toxicol In Vitro 15:413-419, 2001.
96. D Marzin. New approaches to estimating the mutagenic potential of chemicals. Cell Biol Toxicol 15:359-365, 1999.
97. WD Pennie, JD Tugwood, GJ Oliver, I Kimber. Toxicol Sci 54:277-283, 2000.
98. HK Hamadeh, RP Amin, RS Paules, CA Afshari. An overview of toxicogenomics. Curr Issues Mol Biol 4:45-56, 2002.
99. JF Waring, DN Halbert. The promise of toxicogenomics. Curr Opin Mol Ther 4:229-235, 2002.
100. RP Amin, HK Hamadeh, PR Bushel, L Bennett, CA Afshari, RS Paules. Genomic interrogation of mechanism(s) underlying cellular responses to toxicants. Toxicology 181/182:555-563, 2002.
101. MJ Aardema, JT MacGregor. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat Res 499:13-35, 2002.
102. LR Bandara, S Kennedy. Toxicoproteomics: a new preclinical tool. Drug Discov Today 7:411-418, 2002.
103. E Holmes, JK Nicholson, G Tranter. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. Chem Res Toxicol 14:182-191, 2001.
104. JP Shockcor, E Holmes. Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem 2:35-51, 2002.
105. MR Fielden, JB Mathews, KC Fertuck, RG Halgren, TR Zacharewski. In silico approaches to mechanistic and predictive toxicology: an introduction to bio-informatics for toxicologists. Crit Rev Toxicol 32:67-112, 2002.
106. CJ Manly, S Louise-May, JD Hammer. The impact of informatics and computational chemistry on synthesis and screening. Drug Discov Today 6:1101-1110, 2001.
107. DK Agrafiotis, VS Lobanov, FR Salemme. Combinatorial informatics in the postgenomic era. Nat Rev 1:337-346, 2002.
108. J Xu, A Hagler. Chemoinformatics and drug discovery. Molecules 7:566-600, 2002.
109. MG Bures, YC Martin. Computational methods in molecular diversity and combinatorial chemistry. Curr Opin Chem Biol 2:376-380, 1998.
110. P Willett. Similarity and diversity in chemical libraries. Curr Opin Biotechnol 11:104-107, 2000.
111. DK Agrafiotis. Stochastic algorithms for maximizing molecular diversity. J Chem Inf Comput Sci 37:841-851, 1997.
112. RS Pearlman, KM Smith. Software for chemical diversity in the context of accelerated drug discovery. Drugs Future 23:885-895, 1998.
113. RS Pearlman. Novel Software Tools for Addressing Chemical Diversity. Network Science, http://www.netsci.org/Science/Combichem/feature08.html, 1996.
114. TC Kuhler, J Gottfries, TI Oprea, V Sherbukhin, P Svensson. Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces. J Mol Graph Model 18:512-524, 2000.
115. EJ Martin, JM Blaney, MA Siani, DC Spellmeyer, AK Wong, WH Moos. Measuring diversity: experimental design of combinatorial libraries for drug discovery. J Med Chem 38:1431-1436, 1995.
116. EJ Martin, R Critchlow. Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J Comb Chem 1:32-45, 1999.
117. RA Fecik, KE Frank, EJ Gentry, SR Menon, LA Mitscher, H Telikepalli. The search for orally active medications through combinatorial chemistry. Med Res Rev 18:149-185, 1998.
118. SJ Teague, AM Davis, PD Leeson, T Oprea. The design of leadlike combinatorial libraries. Agnew Chem Int Ed 38:3743-3748, 1999.
119. TI Oprea. Current trends in lead discovery: are we looking for the appropriate properties? J Comput Aided Mol Des 16:325-334, 2002.
120. WJ Eagan, WP Walters, MA Murko. Guiding molecules toward drug-likeness. Curr Opin Drug Discov Dev 5:540-549, 2002.
121. MM Hann, AR Leach, G Harper. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41:856-864, 2001.
122. GM Rishton. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 8:86-96, 2003.
123. I Muegge. Selection criteria for drug-like compounds. Med Res Rev 23:302-321, 2003.
124. R Todeschini, V Consonni, Eds. Handbook of Molecular Descriptors. Wienheim, Germany: Wiley-VCH, 2000.
125. A Ajay, WP Walters, MA Murcko. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? J Med Chem 41:3314-3324, 1998.
126. TI Oprea. Property distribution of drug-related chemical databases. J Comput Aided Mol Des 14:251-264, 2000.
127. JF Blake. Chemoinformatics: predicting the physicochemical properties of "drug-like" molecules. Curr Opin Biotechnol 11:104-107, 2000.
128. SD Pickett, IM McLay, DE Clark. Enhancing the hit-to-lead properties of lead optimization libraries. J Chem Inf Comput Sci 40:263-272, 2000.
129. RS Pearlman, KM Smith. Metric validation and the receptor-relevant subspace concept. J Chem Inf Comput Sci 39:28-35, 1999.
130. JG Topliss. Computer-aided drug design in industrial research: a management perspective. In Computer-Aided Drug Design in Industrial Research, EC Herrmann, R Franke, Eds. Berlin: Springer-Verlag, 1995, chap. 2.
131. C Hansch, A Leo, D Hoekman. Exploring QSAR. Hydrophobic, Electronic and Steric Constants. American Chemical Society, 1995.
132. MA Navia, PR Chaturvedi. Design principles for orally bioavailable drugs. Drug Discov Today 1:179-189, 1996.
133. CA Lipinski, F Lombardo, BW Dominy, PJ Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25, 1997.
134. MC Wenlock, RP Austin, P Barton, AM Davis, PD Leeson. A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250-1256, 2003.
135. YH Zhao, J Le, MH Abraham, A Hersey, PJ Eddershaw, CN Luscombe, D Boutina, G Beck, B Sherborne, I Cooper, JA Platts. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 90:749-784, 2001.
136. P Crivori, G Cruciani, PA Carrupt, B Testa. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 43:2204-2216, 2000.
137. KR Korzekwa, JP Jones, JR Gillete. Theoretical studies on cytochrome P-450 mediated hydroxylation: a predictive model for hydrogen atom abstractions. J Am Chem Soc 1112:7042-7046, 1990.
138. SB Singh, LQ Shen, MJ Walker, RP Sheridan. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 46:1330-1336, 2003.
139. S Ekins, CL Waller, PW Swaan, G Cruciani, SA Wrighton, JH Wikel. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251-272, 2001.
140. MP Beavers, X Chen. Structure-based combinatorial library design: methodologies and applications. J Mol Graph Model 20:463-468, 2002.
141. TG Davies, J Bentley, CE Arris, FT Boyle, NJ Curtin, JA Endicott, AE Gibson, BT Golding, RJ Griffin, IR Hardcastle, P Jewsbury, LN Johnson, V Mesguiche, DR Newell, ME Noble, JA Tucker, L Wang, HJ Whitfield. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 9:745-749, 2002.
142. N Green, PN Judson, JJ Langowski, CA Marchant. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, STAR and METEOR. SAR QSAR Environ Res 10:299-314, 1999.
143. G Klopman. Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules. J Am Chem Soc 106:7315-7321, 1984.
144. D Zmuidinavicius, P Japertas, A Petrauskas, R Didziapetris. Progress in toxinformatics: the challenge of predicting acute toxicity. Curr Top Med Chem 3:1301-1314, 2003.
145. PA Bacha, HS Gruver, BK Den Hartog, SY Tamura, RF Nutt. Rule extraction from a mutagenicity data set using adaptively grown phylogenetic-like trees. J Chem Inf Comput Sci 42:1104-1111, 2002.
146. P Gedeck, P Willet. Visual and computational analysis of structure-activity relationships in high-throughput screening data. Curr Opin Struct Biol 5:389-395, 2001.
147. Diva®, Accelrys, Inc. Accelrys is a wholly owned subsidiary of Pharmacopeia, Inc.
148. Spotfire®, Spotfire, Inc., Somerville, MA.
149. Omniviz, OmniViz, Inc., Maynard, MA.
150. G Roberts, GJ Myatt, WP Johnson, KP Cross, PE Blower, Jr. Leadscope: software for exploring large sets of screening data. J Chem Inf Comput Sci 40:1302-1314, 2000.
151. JM McKenna, F Halley, JE Souness, IM McLay, SD Pickett, AJ Collis, K Page, I Ahmed. An algorithm-directed two-component library synthesized via solidphase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors. J Med Chem 45:2173-2184, 2002.
152. G Bravi, DVS Green, MM Hann, AR Leach. PLUMS: a program for the rapid optimization of focused libraries. J Chem Inf Comput Sci 40:1441-1448, 2000.
153. VJ Gillet, P Willet, J Bradshaw, DVS Green. Selecting combinatorial libraries to optimize diversity and physical properties. J Chem Inf Comput Sci 39:169-177, 1999.
154. W Zheng, ST Hung, JT Saunders, GL Seibel. PICCOLO: a tool for combinatorial library design via multicriterion optimization. Pac Symp Biocomput 588-599, 2000.
155. RD Brown, M Hassan, M Waldman. Combinatorial library design for diversity, cost efficiency, and drug-like character. J Mol Graph Model 18:427-437, 2000.
156. J Shimada, S Ekins, C Elkin, EI Shakhnovich, JP Wery. Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs. Targets 1:196-205, 2002.
157. SL Gallion, L Hardy, A Sheldon. Tilting toward targets: biased compound sets. Curr Drug Discov 1:25-27, 2002.
158. AB Beresford, M Tarbit, K Jessing. Application of the Camitro Predictive ADME/Tox Platform for Lead Optimisation. Paper presented at International Business Conferences: 4th Annual Conference on Predictive and Emerging Technologies for Lead Selection and Optimization, November 2001.
159. SL Gallion. Biased Library Design and Parallel Optimization of Ion Channel Modulators. Paper presented at International Business Conferences: Advances in Structure- Guided Drug Discovery, San Diego, CA, November 2002.
160. VJ Gillet, W Khatib, P Willett, PJ Fleming, DVS Green. Combinatorial library design using a multiobjective genetic algorithm. J Chem Inf Comput Sci 42:375-385, 2002.
161. S Ekins, B Boulanger, PW Swaan, MAZ Hupcey. Toward a new age of virtual ADME/TOX and multidimensional drug discovery. J Comput Aided Mol Des 16:381-401, 2002.
162. Admensa Interactive, Inpharmatica Ltd., Cambridge, U.K.